ArticleTranslational psychiatry2015
Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders.
Article in Translational psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Systematic Review and Meta-Analysis on MS-Based Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Bipolar Disorder.International journal of molecular sciences · 2022Pooled it
- Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia.International journal of molecular sciences · 2022Pooled it
- Augmenting Clinical Interventions in Psychiatric Disorders: Systematic Review and Update on Nutrition.Frontiers in psychiatry · 2021Pooled it
- Fatigue in Sjögren's Disease - Integrating Biomedical and Psychosocial Aspects: A Narrative Review.Rheumatology and therapy · 2026Review
- Large-scale proteomic analyses before depression diagnosis reveal novel pathophysiological insights.Molecular psychiatry · 2026Article
- Peripheral biochemical parameters for discrimination between bipolar disorder and major depressive disorder in female patients of reproductive age: a CRP-stratified exploratory study.BMC psychiatry · 2026Article
- Potential biomarkers differentiating major depression from bipolar disorder depressive episodes by Olink Proteomics.BMC psychiatry · 2026Article
- Biopsychosocial correlates of resting and stress-reactive salivary GDF15: preliminary findings.Brain, behavior, and immunity · 2025Article
- Mitochondrial health, prenatal distress, and gestational age: investigation of cf-mtDNA and GDF15 in two pregnancy studies from the USA and Turkey.Mitochondrion · 2025Article
- The energetic stress cytokine GDF15 is elevated in the context of chronic and acute psychosocial stress.bioRxiv : the preprint server for biology · 2025Article
- Bipolar disorder at mixed states and major depressive disorder with mixed features differ in peripheral biochemical parameters.BMC psychiatry · 2025Observational
- Electroacupuncture and vagus nerve stimulation are emerging therapies for hyperemesis gravidarum management.Frontiers in neurology · 2025Review
- Network Pharmacology and Transcriptomics to Explore the Pharmacological Mechanisms of 20(S)-Protopanaxatriol in the Treatment of Depression.International journal of molecular sciences · 2024Article
- Exploring the Role of MMP-9 and MMP-9/TIMP-1 Ratio in Subacute Stroke Recovery: A Prospective Observational Study.International journal of molecular sciences · 2024Observational
- Classifying and clustering mood disorder patients using smartphone data from a feasibility study.NPJ digital medicine · 2023Article
- High mobility group box 1 and a network of other biomolecules influence fatigue in patients with Crohn's disease.Molecular medicine (Cambridge, Mass.) · 2023Article
- Transthyretin Is Commonly Upregulated in the Hippocampus of Two Stress-Induced Depression Mouse Models.International journal of molecular sciences · 2023Article
- Altered circulating GDF-15 level predicts sex hormone imbalance in males with major depressive disorder.BMC psychiatry · 2023Article
- Peripheral biomarkers to predict the diagnosis of bipolar disorder from major depressive disorder in adolescents.European archives of psychiatry and clinical neuroscience · 2022Article
- Alterations in blood proteins in the prodromal stage of bipolar II disorders.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The objective of this study was to determine whether proteomic profiling in serum samples can be utilized in identifying and differentiating mood disorders. A consecutive sample of patients with a confirmed diagnosis of unipolar (UP n=52) or bipolar depression (BP-I n=46, BP-II n=49) and controls (n=141) were recruited. A 7.5-ml blood sample was drawn for proteomic multiplex profiling of 320 proteins utilizing the Myriad RBM Discovery Multi-Analyte Profiling platform. After correcting for multiple testing and adjusting for covariates, growth differentiation factor 15 (GDF-15), hemopexin (HPX), hepsin (HPN), matrix metalloproteinase-7 (MMP-7), retinol-binding protein 4 (RBP-4) and transthyretin (TTR) all showed statistically significant differences among groups. In a series of three post hoc analyses correcting for multiple testing, MMP-7 was significantly different in mood disorder (BP-I+BP-II+UP) vs controls, MMP-7, GDF-15, HPN were significantly different in bipolar cases (BP-I+BP-II) vs controls, and GDF-15, HPX, HPN, RBP-4 and TTR proteins were all significantly different in BP-I vs controls. Good diagnostic accuracy (ROC-AUC⩾0.8) was obtained most notably for GDF-15, RBP-4 and TTR when comparing BP-I vs controls. While based on a small sample not adjusted for medication state, this discovery sample with a conservative method of correction suggests feasibility in using proteomic panels to assist in identifying and distinguishing mood disorders, in particular bipolar I disorder. Replication studies for confirmation, consideration of state vs trait serial assays to delineate proteomic expression of bipolar depression vs previous mania, and utility studies to assess proteomic expression profiling as an advanced decision making tool or companion diagnostic are encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.